“Deucravacitinib Long-Term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s48. https://doi.org/10.25251/skin.6.supp.48.